Related Experiment Video
Updated: Aug 11, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Functionality and acceptability of a new electronic insulin injection pen with a memory feature
Willem J R R Venekamp1, Lisa Kerr, Sherie A Dowsett
1Atrium Medical Centre, Brunssum, The Netherlands. w.venekamp@atriummc.nl
Current Medical Research and Opinion
|February 10, 2006
Summary
The HumaPen Memoir (HPM) is a new electronic insulin pen that demonstrated a favorable benefit-risk profile. This reusable insulin injection device showed good functionality and high patient acceptance in a clinical study.
Area of Science:
- Diabetes Management
- Medical Device Technology
- Pharmacology
Background:
- The HumaPen Memoir (HPM) is a novel reusable insulin injection pen featuring electronic memory to store 16 insulin doses.
- Effective insulin delivery devices are crucial for managing diabetes and improving patient outcomes.
Purpose of the Study:
- To evaluate the functionality of the HumaPen Memoir in delivering set insulin doses.
- To assess the impact of the HPM on patient safety.
- To determine patient and healthcare professional (HCP) acceptance of the HPM.
Main Methods:
- A 6-10 week, multinational, multi-center, open-label, single-arm outpatient study.
- Participants with type 1 or type 2 diabetes used the HPM for prandial or basal insulin injections.
- Data collected on device functionality, adverse events, and patient/HCP acceptance via questionnaires and complaint forms.
Main Results:
- Of 300 participants, 7.6% reported functional complaints (2.5% electronic failures, 4.8% user-related), with no serious adverse events (AEs).
- 81.4% of participants preferred the HPM over their previous insulin pen.
- The HPM received higher ratings for features and ease of use compared to pre-study pens.
Conclusions:
- The HumaPen Memoir exhibited no major functional issues leading to serious AEs in the study.
- The study indicates a favorable benefit-risk profile for the HumaPen Memoir.
- The device demonstrated good functionality and high acceptance among patients and HCPs.
Related Concept Videos
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
